Characterization and quantitation of antiestrogen binding sites in estrogen receptor-positive and -negative human breast cancer cell lines

Cancer Research

Volumn 43, Issue 7, 1983, Pages 3094-3100

  Miller, Margaret Ann ^a   Katzenellenbogen, Benita S ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 (1,2,3,4 TETRAHYDRO 6 METHOXY 2 PHENYL 1 NAPHTHYL)PHENOXY] 1,2 PROPANEDIOL; 6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; ANTIESTROGEN; CIS TAMOXIFEN CITRATE; ESTROGEN RECEPTOR; HORMONE RECEPTOR; NITROMIFENE; RADIOISOTOPE; TAMOXIFEN; UNCLASSIFIED DRUG;

BREAST; BREAST CANCER; CIS TAMOXIFEN; DRUG RECEPTOR BINDING; ENZYME ASSAY; ESTRADIOL H 3; HUMAN; HUMAN CELL; NORNITROMIFENE; PHARMACOKINETICS; TAMOXIFEN H 3;

BINDING SITES; BREAST NEOPLASMS; CELL FRACTIONATION; CELL LINE; COMPARATIVE STUDY; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMAN; RECEPTORS, ESTROGEN; SUPPORT, U.S. GOV'T, P.H.S.; TAMOXIFEN;

EID: 0020569987     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Amar-Costesec, A., and Beaufay, H. A structural basis of enzymatic heterogeneity within liver endoplasmic reticulum. J. Theor. Biol., 89: 217–230, 1981.
2. Black, L. J., and Goode, R. L. Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice. Life Sci., 26: 1453–1458, 1980.
3. Black, L. J., and Goode, R. L. Evidence for biological action of the antiestrogens LY117018 and tamoxifen by different mechanisms. Endocrinology, 109: 987–989, 1981.
4. Black, L. J., Jones, C. D., and Goode, R. L. Differential interaction of antiestrogens with cytosol estrogen receptors. Mol. Cell. Endocr., 22: 95–103, 1981.
5. Bloom, H. J. G., and Boesen, E. Antioestrogens in treatment of breast cancer: value of nafoxidine in 52 advanced cases. Br. Med. J., 2: 7–10, 1974.
6. Burton, K. A. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem. J. 62: 315–323, 1956.
7. Butler, W. B., Kelsey, W. H., and Goran, N. Effects of serum and insulin on the sensitivity of the human breast cancer cell line MCF-7 to estrogen and antiestrogens. Cancer Res., 41: 82–88, 1981.
8. Coezy, E., Borgna, J.L., and Rochefort, H. Tamoxifen and metabolites in MCF-7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res., 42: 317–323, 1982.
9. Eckert, R. L., and Katzenellenbogen, B. S. Physical properties of estrogen receptor complexes in MCF-7 human breast cancer cells: differences with antiestrogen and estrogen. J. Biol. Chem., 257: 8840–8846, 1982.
10. Eckert, R. L., and Katzenellenbogen, B. S. Effects of estrogens and antiestrogens on estrogen receptor dynamics and the induction of progesterone receptor in MCF-7 human breast cancer ceUs. Cancer Res., 42: 139–144,1982.
11. Faye, J. C., Jozan, S., and Bayard, F. Mechanism of action of antiestrogens of the triphenylethylene type in MCF-7 cells. In: proceedings of the 64th Annual Endocrine Society Meeting, Abstract 376, p. 173. Baltimore: Williams & Wilkins, 1982.
12. Faye, J. C., Lassere, B., Bayard, F. Antiestrogen specific high affinity saturable binding sites in rat uterine cytosol. Biochem. Biophys. Res. Commun., 93: 1225–1231, 1980.
13. Fisher, B., Redmond, C., Brown, A., and other NSABP Investigators. Treatment of primary breast cancer with chemotherapy and tamoxifen. N. Engl. J. Med., 305: 1–6, 1981.
14. Glock, G. E. and McLean, P. Further studies on the properties and assay of glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase of rat liver. Biochem. J., 55: 400–408, 1953.
15. Gulino, A., and Pasqualini, J. R. Heterogeneity of binding sites for tamoxifen and tamoxifen derivatives in estrogen target and nontarget fetal organs of guinea pig. Cancer Res., 42: 1913–1921, 1982.
16. Harper, M. J. K., and Walpole, A. L. A new derivative of triphenylethylene and mode of action in rats. J. Reprod. Fertil., 13: 101–119, 1967.
17. Heuson, J. C., Engelsman, E., Blonk-vander Wijst, J., Maass, H., Drochmans, A., Michel, J., Nowakowski, H., and Gorins, A. Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: a European Organization for Research on Treatment of Cancer study. Br. Med. J., 2: 711–713, 1975.
18. Horwitz, K. B., and McGuire, W. L. Antiestrogens: mechanism of action and effects in breast cancer. In: W. L. McGuire (ed.), Breast Cancer: Advances in Research and Treatment, Vol. 2, pp. 155–204. New York: Plenum Publishing Corp., 1978.
19. Horwitz, K. B., and McGuire, W. L. Estrogen control of progesterone receptor in human breast cancer. J. Biol. Chem., 253: 2223–2228, 1978.
20. Hubscher, G., and West, G. R. Specific assays of some phosphatases in subcellular fractions of small intestinal mucosa. Nature (Lond.), 205: 799–800, 1965.
21. Jordan, V. C., Haldemann, B., and Allen, K. E. Geometric isomers of substituted triphenylethylenes and antiestrogen action. Endocrinology, 108: 1353–1361, 1981.
22. Katzenellenbogen, B. S., Bhakoo, H. S., Ferguson, E. R., Lan, N. C., Tatee, T., Tsai, T. L., and Katzenellenbogen, J. A. Estrogen and antiestrogen action in reproductive tissues and tumors. Recent Prog. Horm. Res., 35: 259–300, 1979.
23. Katzenellenbogen, B. S., Pavlik, E. J., Robertson, D. W., and Katzenellenbo gen, J. A. Interaction of a high affinity antiestrogen (α-[4-pyrrolidinoethoxy] phenyt-4-hydroxy-α-nitrostilbene, CI628M) with uterine estrogen receptors. J. Biol. Chem., 256: 2980–2915, 1981.
24. Lippman, M., Bolan, G., and Huff, K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res., 36: 4595–4601, 1976.
25. Macindoe, J. H., Woods, G. R., and Lee, F. J. The specific binding of androgens and the subsequent distribution of androgen-receptor complexes within MCF-7 human breast cancer cells. Steroids, 38: 439–452, 1981.
26. McGuire, W. L. Steroid receptor sites in cancer therapy. Adv. Intern. Med., 24: 127–140, 1979.
27. McGuire, W. L., Chamness, G. C., Horwitz, K. B., and Zava, D. T. Hormones and their receptors in breast cancer. In: B. O’Malley and L. Bimbaumer (eds.), Receptors and Hormone Action, Vol. 2. pp. 401–441. New York: Academic Press, Inc., 1978.
28. Murphy, L. C., and Sutherland, R. L. Modifications in the aminoether side chain of clomiphene influence affinity for a specific antiestrogen binding site in MCF-7 cell cytosol. Biochem. Biophys. Res. Commun., 100: 1353–1369, 1981.
29. Nawata, H., Bronzert, D., and Lippman, M. E. Isolation and characterization of a tamoxifen-resistant cell line derived from MCF-7 human breast cancer cells. J. Biol. Chem., 256: 5016–5021, 1981.
30. Parikh, I., Anderson, W. L., and Neame, P. Identification of high affinity estrogen binding sites in calf uterine microsomal membranes. J. Biol. Chem., 255: 10266–10270, 1980.
31. Peterson, G. L. A simplification of the protein method of Lowry et al. which is more generally applicable. Anal. Biochem., 83: 346–356, 1977.
32. Robertson, D. W., and Katzenellenbogen, J. A. Synthesis of the E and Z isomers of the antiestrogen tamoxifen and its metabolite, hydroxytamoxifen, in tritium-labeled form. J. Org. Chem., 47: 2387–2393, 1982.
33. Robertson, D. W., Katzenellenbogen, J. A., Long, D. J., Rorke, E. A., and Katzenellenbogen, B. S. Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J. Steroid Biochem., 16: 1–13, 1982.
34. Scholl, S., Huff, K., and Lippman, M. E. Effects of LY117018 on MCF-7 human breast cancer cells. In: Proceedings 63rd Annual Endocrine Society Meeting, Abstract 175, p. 126. Baltimore: Williams and Wilkins, 1981.
35. Sudo, K., Miller, M. A., Monsma, F. J., Jr., and Katzenellenbogen, B. S. Antiestrogen-specific binding sites: subcellular localization, distribution and ligand specificity in rat tissues and human breast cancer cells. In: Proceedings 64th Annual Endocrine Society Meeting, Abstract 57, p. 94. Baltimore: Williams and Wilkins, 1982.
36. Sudo, K., Monsma, F. J., Jr., and Katzenellenbogen, B. S. Antiestrogen binding sites distinct from the estrogen receptor: subcellular localization, ligand specificity, and distribution in tissues of the rat. Endocrinology, 112: 425–434, 1983.
37. Sutherland, R. L., and Foo, M. S. Differential binding of antiestrogens by rat uterine and chick oviduct cytosol. Biochem. Biophys. Res. Commun., 92: 183–191, 1979.
38. Sutherland, R. L., Foo, M. S., Green, M. D., Waybourne, A. M., and Krozowski, Z. S. High affinity antiestrogen binding site distinct from the estrogen receptor. Nature (Lond.), 288: 273–275, 1980.
39. Sutherland, R. L., and Murphy, L. C. The binding of tamoxifen to human mammary carcinoma cytosol. Eur. J. Cancer, 16: 1141–1148, 1980.
40. Szego, C. M., Seeler, B. J., Steadman, R. A., Hill, D. F., Kimura, A. K., and Roberts, J. A. The lysosomal membrane complex: focal point of primary steroid hormone action. Biochem. J., 123: 523–538, 1971.
41. Tormey, D. C., Simon, R. M., Lippman, M. E., Bull, J. M., and Myers, C. E. Evaluation of tamoxifen dose in advanced breast cancer: a progress report. Cancer Treat. Rep., 60: 1451–1459, 1976.